UTILISATION D'UN RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE SOLUBLE RECOMBINANT HUMAIN À LONGUE ACTION DANS LA PRÉPARATION DE MÉDICAMENTS POUR LA PRÉVENTION ET LE TRAITEMENT DE MALADIES HÉPATIQUES CHRONIQUES ET D'UNE ATTEINTE HÉPATIQUE SÉVÈRE
The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis α receptor (HusTNFR) and belongs to the gene engineering technology and gene function application field. This invention uses type I or type II long-acting HusTNFR (LHusTNFR) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models. The results showed that LHusTNFR, which has a half-life of 12-140 hours, shows excellent efficacy for preventing the development of severe liver injury on chronic liver disease and for treating early-stage severe liver injury on chronic liver disease. It also significantly reduced the mortality of the model animals. Its efficacy for the prevention and treatment of early-stage severe liver injury on chronic liver disease was significantly better than that of non-LHusTNFR.
